Search alternatives:
non decrease » point decrease (Expand Search), note decreased (Expand Search), fold decrease (Expand Search)
mg decrease » _ decrease (Expand Search), we decrease (Expand Search), mean decrease (Expand Search)
nn decrease » _ decrease (Expand Search), mean decrease (Expand Search), gy decreased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
non decrease » point decrease (Expand Search), note decreased (Expand Search), fold decrease (Expand Search)
mg decrease » _ decrease (Expand Search), we decrease (Expand Search), mean decrease (Expand Search)
nn decrease » _ decrease (Expand Search), mean decrease (Expand Search), gy decreased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
-
81
Non-Steady-State Fickian Diffusion Models Decrease the Estimated Gel Layer Diffusion Coefficient Uncertainty for Diffusive Gradients in Thin-Films Passive Samplers
Published 2023“…A finite difference model (FDM) developed based on Fick’s second law with non-steady-state (N-SS) flux decreased uncertainty in <i>D</i><sub>Gel</sub> tenfold. …”
-
82
-
83
-
84
The decrease or inhibition of Hsp90 induced REST degradation.
Published 2019“…<p>(A) Effect of Hsp90α ASO on cell viability. Differentiated SH-SY5Y cells were transfected with different concentrations of Hsp90α ASO. …”
-
85
-
86
Data_Sheet_1_Effectiveness of non-pharmaceutical interventions in nine fields of activity to decrease SARS-CoV-2 transmission (Spain, September 2020–May 2021).PDF
Published 2023“…In a reduced model with seven fields, culture and leisure no longer had a significant effect while ceremonies decreased transmission by 5% (0.95; 0, 0.96). …”
-
87
-
88
-
89
Inclusion of SRRM4-regulated exons is decreased in tumors and cancer cell lines.
Published 2021“…Red points are exons with PSI decreasing by at least 5% in at least 1 tumor type. …”
-
90
-
91
-
92
-
93
-
94
-
95
-
96
Table 1_Previous treatment decreases efficacy of pralsetinib in RET fusion-positive non-small-cell lung cancer.doc
Published 2025“…Background<p>Pralsetinib is a selective RET inhibitor. The ARROW trial revealed that RET fusion-positive non-small-cell lung cancer (NSCLC) can benefit from pralsetinib with tolerable adverse events (AEs). …”
-
97
-
98
-
99
-
100